Amanta Healthcare Reports Zero Deviation in IPO Proceeds Utilization for Sep'26 Quarter
Amanta Healthcare Ltd · Others (Uncategorized) · 03 Nov 2026, 11:07 pm
Amanta Healthcare Reports Zero Deviation in IPO Proceeds Utilization for Sep'26 Quarter Amanta Healthcare confirmed zero deviation in utilizing its ₹126 crore IPO proceeds for the quarter ended 30th Sep'26. Monitored by CRISIL Ratings, cumulative deployment reached ₹67.02 crore of the ₹70.00 crore allocated for the SteriPort manufacturing line capex and ₹7.94 crore of the ₹30.13 crore earmarked for the SVP line capex at Hariyala, Gujarat. Issue expenses were fully utilized at ₹22.85 crore (adjusted for GST), with general corporate purpose deployment at ₹3.02 crore.
Original exchange filing (PDF)
More announcements from Amanta Healthcare Ltd
- Company Response On The Spurt In Volume Of Security Across Exchanges · 14 Nov 2026
- The Exchange has sought clarification from Amanta Healthcare Ltd on November 13, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. · 13 Nov 2026
- Transcript of Post Results Conference call held on November 4, 2026 · 09 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jitendrakumar Jashbhai Patel · 09 Nov 2026
- submission of Disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 (the "Insider Trading Regulations") · 07 Nov 2026
- submission of Audio Recording of Post Results Conference Call held on November 4, 2026 · 04 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 · 04 Nov 2026
- Announcement under Regulation 30 - Investor Presentation · 04 Nov 2026
